Overall survival | ||
Variable | HR (95% Cl) | P value |
Age | 1.01 (0.98 to 1.04) | 0.51 |
Stage 4 | 1.53 (0.65 to 3.58) | 0.33 |
CA-125 | 1.00 (1.00 to 1.00) | 0.036 |
Debulking | ||
R1 | 1.00 (0.33 to 2.98) | 0.99 |
R2 | 2.06 (1.12 to 3.78) | 0.019 |
P-TME | M-TME | |||
DC-LAMP | 0.74 (0.58 to 0.95) | 0.018 | 0.74 (0.60 to 0.92) | 0.006 |
CD8 | 0.87 (0.75 to 0.99) | 0.039 | 0.90 (0.78 to 1.03) | 0.11 |
CD20 | 0.35 (0.09 to 1.33) | 0.12 | 0.85 (0.64 to 1.13) | 0.26 |
NKp46 | 0.83 (0.54 to 1.27) | 0.39 | 0.95 (0.72 to 1.25) | 0.70 |
M2-like TAMs | 0.15 (0.01 to 3.20) | 0.22 | 6.74 (1.58 to 28.68) | 0.009 |
CA-125, cancer antigen 125; DC-LAMP, lysosomal-associated membrane protein; M-TME, metastatic tumor microenvironment; NK, natural killer; P-TME, primary tumor microenvironment; TAMs, tumor-associated macrophages .